Sana Biotechnology will dish out up to $204 million in biobucks to gain nonexclusive access to a BCMA CAR construct from IASO Biotherapeutics and partner Innovent Biologics.

The FDA rejected BeyondSpring’s drug for chemotherapy-induced neutropenia (CIN) in late-November, and now the biotech is letting go 35% of its U.S. staff.

It’s been more than two years since a substantial update has been provided on bluebird bio and Bristol Myers Squibb’s partnership on a multiple myeloma CAR-T. Now, development of the treatment is being shut down.

Regeneron and 2seventy bio have revealed the candidate spearheading their CAR-T pact. Working with the bluebird bio spinout, Regeneron has selected MUC16 as the target for the first CAR-based solid tumor program.

Welcome to Day 2 of the annual J. P. Morgan Healthcare Conference, gone virtual once more.

Amgen is advancing its collaboration with AI-enabled antibody design shop BigHat Biosciences. With the first phase of the previously undisclosed partnership validating the technology, Amgen has tasked BigHat with creating a lead panel of VHH antibodies.

Sarepta Therapeutics could ask the FDA as soon as next year to approve its gene transfer therapy for Duchenne muscular dystrophy, the biotech said Monday at the annual J.P. Morgan Healthcare Conference.

23andMe’s genetic analysis can connect people with long-lost family members, teach them about how their DNA can affect their health and lifestyle choices and, now, help determine their hereditary risk of prostate cancer.

Seer has launched its system for categorizing the tens of thousands of proteins within the human body that drive the biologic functions of both life and disease.

Acadia Pharmaceuticals is looking to Stoke Therapeutics to breathe some air into its pipeline, with a $60 million upfront research pact to develop drugs for rare genetic diseases of the central nervous system.